Gene-editing approach may one day cure chronic hepatitis B: Study
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
Marisa Wexler, MS, Senior Science Writer—
Articles by Marisa Wexler
New trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
Age at Kasai, spleen issues key to biliary atresia outcomes
Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more likely to have poor outcomes…
Canada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…
FDA gives conditional approval to Wegovy for some liver patients
The U.S. Food and Drug Administration (FDA) has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat certain people with metabolic dysfunction-associated steatohepatitis (MASH), a…
NorUDCA becomes first MASLD therapy approved in India
India’s Central Drugs Standard Control Organization has approved the oral therapy nor-ursodeoxycholic acid (NorUDCA) for people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
AI tool uses liver tests to ID genetic forms of cholestasis in infants
A new artificial intelligence (AI) algorithm can help identify babies with genetic forms of cholestasis, including progressive familial intrahepatic cholestasis (PFIC), using data from…
Fatty liver disease linked to projected rise in liver cancer
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…
Study finds a new player behind liver scarring in biliary atresia
A new study has uncovered a key mechanism behind the liver scarring seen in biliary atresia (BA), a rare liver disease in infants. Two…
3 trials of Vir’s hepatitis D combo treatment now up and running
The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment of tobevibart and elebsiran against…